JT
Highly rated in
25
conditions
Highly rated in
25
conditions
Check Dr. Joni A. Tilford's experience treating your condition:
About Dr. Joni A. Tilford

Joni Tilford is a Hematologist Oncology specialist and an Oncologist in Lincoln, Nebraska. Tilford has been practicing medicine for over 25 years and is highly rated in 25 conditions, according to our data. Her top areas of expertise are Lung Cancer, Paget Disease of the Breast, Inflammatory Breast Cancer, Pleuropulmonary Blastoma, and Bone Marrow Aspiration. She is licensed to treat patients in Nebraska. Tilford is currently accepting new patients.

Her clinical research consists of co-authoring 1 peer reviewed article and participating in 16 clinical trials in the past 15 years.

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Joni A. Tilford it is best to call her office and ask if your insurance is accepted.

Accepts Medicare

Dr. Joni A. Tilford accepts the following insurance:

  •  Bright Health
  •  Oscar
  •  Medica
  •  Nebraska Total Care

Call to see if your plan is accepted.
Locations
3901 Pine Lake Rd, Lincoln, NE 68516
Other Locations
201 S 68th St Pl, Lincoln, NE 68510
Background & Education
Graduate Institution
University Of Nebraska College Of Medicine, 1997
Specialties
Hematology Oncology
Oncology
Licenses
Internal Medicine in NE
Hospital Affiliations
Beatrice Community Hospital & Health Center
CHI Health St Elizabeth
Bryan East Campus
York General Hospital
Nebraska Medical Center
Boone County Health Center
Memorial Health Care Systems
Crete Area Medical Center
Jefferson Community Health & Life
Kearney Regional Medical Center
Languages Spoken
English
Gender
Female
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


16 Clinical Trials

A Phase II Study of Checkpoint Blockade Immunotherapy in Patients With Somatically Hypermutated Recurrent WHO Grade 4 Glioma
Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study
Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)
A Randomized Phase 2 Trial of Encorafenib + Binimetinib + Nivolumab vs Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
Randomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab Versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response
Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Olanzapine With or Without Fosaprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)in Patients Receiving Highly Emetogenic Chemotherapy (HEC): A Phase III Randomized, Double Blind, Placebo-Controlled Trial
A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
View 4 Less Clinical Trials -

Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors